Home LiteratureArticle Details
PMID: 15161795 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up.

Diabetes care ·Vol. 27 ·No. 6 ·2004-06-00 ·Pages 1399-404

Barker JM, Goehrig SH, Barriga K, Hoffman M, Slover R, Eisenbarth GS, Norris JM, Klingensmith GJ, Rewers M, DAISY study

Abstract

The objective of this study was to determine whether earlier diagnosis of diabetes in prospectively followed autoantibody-positive children lowered onset morbidity and improved the clinical course after diagnosis. The Diabetes Autoimmunity Study in the Young (DAISY) follows genetically at-risk children for the development of diabetes. Increased genetic risk is identified by family history of type 1 diabetes or expression of diabetes-associated HLA genotypes. Of the 2,140 prospectively followed children, 112 have developed islet autoantibodies and 30 have progressed to diabetes. Diabetes onset characteristics and early clinical course of these 30 children followed to diabetes were compared with those of 101 age- and sex-matched children concurrently diagnosed with diabetes in the community. Pre-diabetic children followed to diabetes were less often hospitalized than the community cases (3.3 vs. 44%; P < 0.0001). They had a lower mean HbA(1c) at onset (7.2 vs. 10.9%; P < 0.0001) and 1 month after diagnosis (6.9 vs. 8.6%; P < 0.0001) but not after 6 months of diabetes. The mean insulin dose was lower in the DAISY group at 1 (0.30 vs. 0.51 U. kg(-1). day(-1); P = 0.003), 6 (0.37 vs. 0.58; P = 0.001), and 12 months (0.57 vs. 0.72; P = 0.03). There was no difference in growth parameters between the two groups. Comparisons limited to children with a family history of type 1 diabetes in both groups showed a similar pattern. Childhood type 1 diabetes diagnosed through a screening and follow-up program has a less severe onset and a milder clinical course in the first year after diagnosis.

MeSH Terms
Autoantibodies/blood Child Colorado Diabetes Mellitus, Type 1/diagnosis,immunology,physiopathology Follow-Up Studies Hospitalization/statistics & numerical data Humans Infant, Newborn Mass Screening/standards Prediabetic State/diagnosis,immunology,physiopathology Treatment Outcome
Chemicals
Autoantibodies
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Barker Jennifer M
Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, 4200 East Ninth Ave., Box B140, Denver, CO 80262. jennifer.barker@uchsc.edu
Goehrig Stephanie H
Barriga Katherine
Hoffman Michelle
Slover Robert
Eisenbarth George S
Norris Jill M
Klingensmith Georgeanna J
Rewers Marian
DAISY study
Article Info
Journal
Diabetes care
Abbr.
Diabetes Care
ISSN
0149-5992
Published
2004-06-00
Pages
1399-404
Language
English
Region
United States
NLM ID
7805975
Subset
IM
Grants
NIDDK NIH HHS · DK 32083 · United States
NIDDK NIH HHS · DK 50979 · United States
NIDDK NIH HHS · P30 DK 57516 · United States
NIDDK NIH HHS · R01 DK 32493 · United States
NIAID NIH HHS · U01 AI 50864 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com